New York State Common Retirement Fund
VRDN icon

New York State Common Retirement Fund’s Viridian Therapeutics VRDN Stock Holding History

New York State Common Retirement Fund’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$583K Sell
31,719
-12,656
-29% -$204K ﹤0.01% 1947
2026
Q1 		$868K Buy
44,375
+13,655
+44% +$406K ﹤0.01% 1707
2025
Q4 		$956K Buy
30,720
+11,001
+56% +$302K ﹤0.01% 1728
2025
Q3 		$426K Hold
19,719
– – ﹤0.01% 2003
2025
Q2 		$276K Hold
19,719
– – ﹤0.01% 2126
2025
Q1 		$266K Hold
19,719
– – ﹤0.01% 2114
2024
Q4 		$378K Hold
19,719
– – ﹤0.01% 2037
2024
Q3 		$449K Hold
19,719
– – ﹤0.01% 1976
2024
Q2 		$257K Buy
19,719
+1,773
+10% +$24.5K ﹤0.01% 2319
2024
Q1 		$314K Buy
17,946
+451
+3% +$8.74K ﹤0.01% 2263
2023
Q4 		$378K Buy
17,495
+1,545
+10% +$24.4K ﹤0.01% 2210
2023
Q3 		$236K Buy
15,950
+155
+1% +$2.96K ﹤0.01% 2352
2023
Q2 		$376K Sell
15,795
-4,133
-21% -$106K ﹤0.01% 2215
2023
Q1 		$513K Sell
19,928
-2,892
-13% -$92.7K ﹤0.01% 2163
2022
Q4 		$666K Buy
22,820
+4,804
+27% +$111K ﹤0.01% 2174
2022
Q3 		$363K Buy
18,016
+216
+1% +$3.88K ﹤0.01% 2497
2022
Q2 		$206K Buy
+17,800
New +$239K ﹤0.01% 2793
2019
Q2 		– Sell
-1,893
Closed -$79K – 3296
2019
Q1 		$79K Hold
1,893
– – ﹤0.01% 3007
2018
Q4 		$86K Hold
1,893
– – ﹤0.01% 2993
2018
Q3 		$158K Hold
1,893
– – ﹤0.01% 2929
2018
Q2 		$182K Buy
1,893
+993
+110% +$105K ﹤0.01% 2910
2018
Q1 		$95K Hold
900
– – ﹤0.01% 2965
2017
Q4 		$141K Hold
900
– – ﹤0.01% 2895
2017
Q3 		$124K Hold
900
– – ﹤0.01% 2957
2017
Q2 		$175K Buy
+900
New +$152K ﹤0.01% 2908

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

New York State Common Retirement Fund's VRDN Position: Q2 2026 in Review

New York State Common Retirement Fund reduced its Viridian Therapeutics (VRDN) stake by 29% in Q2 2026, selling an estimated $204K and leaving 31,719 shares worth $583K. The position accounts for ﹤0.01% of the portfolio, ranked #1947.

New York State Common Retirement Fund first reported a position in VRDN in Q2 2017 and has held it in 25 quarters since. The position peaked at $956K in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • New York State Common Retirement Fund held 31,719 shares of Viridian Therapeutics worth $583K as of Q2 2026.
  • New York State Common Retirement Fund sold 12,656 Viridian Therapeutics shares in Q2 2026, an estimated $204K.
  • Viridian Therapeutics made up ﹤0.01% of New York State Common Retirement Fund's portfolio in Q2 2026, its #1947 holding.
  • New York State Common Retirement Fund first reported a position in Viridian Therapeutics in Q2 2017 and has held it in 25 quarters since.
  • New York State Common Retirement Fund's Viridian Therapeutics position peaked at $956K in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.